TNFRSF17 and AL amyloidosis: A preclinical study demonstrated that CAR-T cell therapy targeting both BCMA and GPRC5D can reduce relapse caused by BCMA antigen escape and eliminate BCMA-negative multiple myeloma cells in a mouse model (23).